Investing.com··Nathan ReiffLilly's Double-Beat Widens GLP-1 Gap as Foundayo Pill Transforms Market
Eli Lilly beats Q1 earnings, raises $2B guidance, and wins FDA approval for Foundayo, the first unrestricted oral GLP-1, widening gap over Novo Nordisk.
LLYNVOFDA approvalweight loss medications